MEDIMMUNE, LLC. for MEDIMMUNE LLC
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 3187/Pub. L. No. 112-144 - Food and Drug Administration Safety and Innovation Act H.R. 2405/S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization, provisions relating to pandemic influenza vaccine development H.R. 2679 - Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early Reauthorization Act, provisions relating to patient safety study and report Issues related to securing the pharmaceutical distribution system; enactment of federal excise tax for seasonal influenza vaccines and coverage of quadrivalent influenza vaccines under the Vaccine Injury Compensation Program; reimbursement of vaccines and related services; implementation of H.R. 3590/Pub. L. No. 111-148, the Patient Protection and Affordable Care Act; Medicaid coverage and reimbursement; biologics data exclusivity; and, debt and deficit reduction proposals on Medicaid federal funding, Medicaid rebates, and Medicare Part D rebates.
Foreign entity interest: As the ultimate parent of MedImmune, LLC, AstraZeneca PLC has interests in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN RANDALL BUCKLEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.